Breakthrough £90,000 Alzheimer’s drugs unlikely to benefit patients, report suggests
Influential analysis has concluded that "breakthrough" Alzheimer's drugs are unlikely to benefit patients. Read the BBC article "Breakthrough £90,000 Alzheimer's drugs unlikely to benefit patients, report suggests".